211 related articles for article (PubMed ID: 21449979)
1. hERG subunit composition determines differential drug sensitivity.
Abi-Gerges N; Holkham H; Jones EM; Pollard CE; Valentin JP; Robertson GA
Br J Pharmacol; 2011 Sep; 164(2b):419-32. PubMed ID: 21449979
[TBL] [Abstract][Full Text] [Related]
2. Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome.
Sale H; Wang J; O'Hara TJ; Tester DJ; Phartiyal P; He JQ; Rudy Y; Ackerman MJ; Robertson GA
Circ Res; 2008 Sep; 103(7):e81-95. PubMed ID: 18776039
[TBL] [Abstract][Full Text] [Related]
3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Rajamani S; Eckhardt LL; Valdivia CR; Klemens CA; Gillman BM; Anderson CL; Holzem KM; Delisle BP; Anson BD; Makielski JC; January CT
Br J Pharmacol; 2006 Nov; 149(5):481-9. PubMed ID: 16967046
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
6. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
7. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
8. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
[TBL] [Abstract][Full Text] [Related]
10. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
11. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
12. hERG 1a LQT2 C-terminus truncation mutants display hERG 1b-dependent dominant negative mechanisms.
Puckerin A; Aromolaran KA; Chang DD; Zukin RS; Colecraft HM; Boutjdir M; Aromolaran AS
Heart Rhythm; 2016 May; 13(5):1121-1130. PubMed ID: 26775140
[TBL] [Abstract][Full Text] [Related]
13. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
14. Drug block of I(kr): model systems and relevance to human arrhythmias.
Yang T; Snyders D; Roden DM
J Cardiovasc Pharmacol; 2001 Nov; 38(5):737-44. PubMed ID: 11602820
[TBL] [Abstract][Full Text] [Related]
15. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
16. hERG 1b is critical for human cardiac repolarization.
Jones DK; Liu F; Vaidyanathan R; Eckhardt LL; Trudeau MC; Robertson GA
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):18073-7. PubMed ID: 25453103
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
19. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
20. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
